Search
Results: 79
Methods for handling longitudinal outcome processes truncated by dropout and death.
Cohort data are often incomplete because some subjects drop out of the study, and inverse probability weighting (IPW), multiple imputation (MI), and linear increments (LI) are methods that deal with such missing data. In cohort...
A comparison of parametric models for the investigation of the shape of cognitive change in the older population.
Sample size and classification error for Bayesian change-point models with unlabelled sub-groups and incomplete follow-up.
Change-point Mini-Mental State Examination broken-stick change-point regression classification cognitive decline Sample Size simulation study Bayes Theorem Cognitive Dysfunction Data Interpretation Statistical Humans Markov Chains Models Statistical Monte Carlo Method Neuropsychological Tests Sample Size
Assessing and disclosing test results for 'mild cognitive impairment'
BACKGROUND: Mild cognitive impairment (MCI) is a condition that exists between normal healthy ageing and dementia with an uncertain aetiology and prognosis. This uncertainty creates a complex dynamic between the clinicians'...
Mediterranean diet adherence is associated with lower dementia risk, independent of genetic predisposition
Oliver M Shannon, Janice M Ranson, Sarah Gregory, Helen Macpherson, Catherine Milte, Marleen Lentjes, Angela Mulligan, Claire McEvoy, Alex Griffiths, Jamie Matu, Tom R Hill, Ashley Adamson, Mario Siervo, Anne Marie Minihane, Graciela Muniz-Tererra, Craig Ritchie, John C Mathers, David J Llewellyn, Emma Stevenson
Mar 14, 2023
Assessing and disclosing test results for 'mild cognitive impairment'
BACKGROUND: Mild cognitive impairment (MCI) is a condition that exists between normal healthy ageing and dementia with an uncertain aetiology and prognosis. This uncertainty creates a complex dynamic between the clinicians'...
A Novel Examination of Successful Aging Trajectories at the End of Life.
Theodore D Cosco, Blossom CM Stephan, Graciela Muniz, Carol Brayne, CC75C Study Collaboration
Sep 27, 2018
A successful aging (SA) index was captured in a longitudinal population-based cohort study of individuals aged 75 and older and examined longitudinally using growth mixture modelling (GMM) to identify groups with similar...
Higher midlife CAIDE score is associated with increased brain atrophy in a cohort of cognitively healthy middle-aged individuals
Xulin Liu, Maria-Eleni Dounavi, Karen Ritchie, Katie Wells, Craig W. Ritchie, Li Su, Graciela Muniz-Terrera, John T. O’Brien
Apr 24, 2021
Abstract: Background: Structural brain changes associated with Alzheimer’s disease (AD) can occur decades before the onset of symptoms. The Cardiovascular Risk Factors, Aging, and Dementia (CAIDE) score has been suggested to be...
Evidence of cerebral hemodynamic dysregulation in middle-aged APOE ε4 carriers
Maria-Eleni Dounavi, Audrey Low, Elizabeth F McKiernan, Elijah Mak, Graciela Muniz-Terrera, Karen Ritchie, Craig W Ritchie, Li Su, John T O'Brien
Oct 23, 2021
Accumulating evidence suggests vascular dysregulation in preclinical Alzheimer's disease. In this study, cerebral hemodynamics and their coupling with cognition in middle-aged apolipoprotein ε4 carriers (APOEε4+) were...
APOE arterial spin labelling cerebral blood flow Dementia Perfusion Adult Alzheimer Disease Apolipoprotein E4 Atrophy Case-Control Studies Cerebral Arteries Cerebrovascular Circulation Cognition Female Follow-Up Studies Hematocrit Heterozygote Humans Linear Models Magnetic Resonance Imaging Male Middle Aged Neuropsychological Tests Neurovascular Coupling
Proximity to dementia onset and multi-modal neuroimaging changes
Elijah Mak, Maria-Eleni Dounavi, Audrey Low, Stephen F Carter, Elizabeth McKiernan, Guy B Williams, P Simon Jones, Isabelle Carriere, Graciela Terrera Muniz, Karen Ritchie, Craig Ritchie, Li Su, John T O'Brien
Jan 12, 2021
Higher midlife CAIDE score is associated with increased brain atrophy in a cohort of cognitively healthy middle-aged individuals.
Xulin Liu, Maria-Eleni Dounavi, Karen Ritchie, Katie Wells, Craig W Ritchie, Li Su, Graciela Muniz-Terrera, John T O'Brien
Dec 23, 2020
BACKGROUND: Structural brain changes associated with Alzheimer's disease (AD) can occur decades before the onset of symptoms. The Cardiovascular Risk Factors, Aging, and Dementia (CAIDE) score has been suggested to be associated...
Inherited risk of dementia and the progression of cerebral small vessel disease and inflammatory markers in cognitively healthy midlife adults
Audrey Low, Li Su, James D Stefaniak, Elijah Mak, Maria-Eleni Dounavi, Graciela Muniz-Terrera, Karen Ritchie, Craig W Ritchie, Hugh S Markus, John T O'Brien
Nov 11, 2020
Cerebral small vessel disease (SVD) and inflammation are increasingly recognized as key contributors to Alzheimer's disease (AD), although the timing, trajectory, and relation between them early in the disease process is...
APOE4 Alzheimer's Disease Cerebral microbleeds cerebral small vessel disease Inflammation Risk Factors White matter hyperintensities Alzheimer Disease Apolipoprotein E4 Biomarkers C-Reactive Protein cerebral small vessel diseases Cognition Dementia Disease Progression Female Fibrinogen Genetic Association Studies Genetic Predisposition to Disease healthy aging Heterozygote Humans Inflammasomes Male Middle Aged risk white matter
Modifiable and non-modifiable risk factors of dementia on midlife cerebral small vessel disease in cognitively healthy middle-aged adults
Abstract
Background
Considerable overlap exists between the risk factors of dementia and cerebral small vessel disease (SVD)....
Audrey Low, Maria A Prats-Sedano, Elizabeth McKiernan, Stephen F Carter, James D Stefaniak, Stefania Nannoni, Li Su, Maria-Eleni Dounavi, Graciela Muniz-Terrera, Karen Ritchie, Brian Lawlor, Lorina Naci, Paresh Malhotra, Clare Mackay, Ivan Koychev, Craig W Ritchie, Hugh S Markus, John T O’Brien
Oct 12, 2022
Macrostructural brain alterations at midlife are connected to cardiovascular and not inherited risk of future dementia
Maria-Eleni Dounavi, Coco Newton, Natalie Jenkins, Elijah Mak, Audrey Low, Graciela Muniz-Terrera, Guy B Williams, Brian Lawlor, Lorina Naci, Paresh Malhotra, Clare E Mackay, Ivan Koychev, Karen Ritchie, Craig W Ritchie, Li Su, John T O'Brien
Jul 19, 2022
BACKGROUND: Macrostructural brain alterations in the form of brain atrophy or cortical thinning typically occur during the prodromal Alzheimer's disease stage. Mixed findings largely dependent on the age of the examined cohorts...
CAIDE dementia risk score relates to severity and progression of cerebral small vessel disease in healthy midlife adults
Audrey Low, Maria A Prats-Sedano, James D Stefaniak, Elizabeth Frances McKiernan, Stephen F Carter, Maria-Eleni Douvani, Elijah Mak, Li Su, Olivia Stupart, Graciela Muniz, Karen Ritchie, Craig W Ritchie, Hugh S Markus, John Tiernan O'Brien
Feb 14, 2022
Education and Successful Aging Trajectories
As the population ages, interest is increasing in studying aging well. However, more refined means of examining predictors of biopsychosocial conceptualizations of successful aging (SA) are required. Existing evidence of the...
Prescreening for European Prevention of Alzheimer Dementia (EPAD) trial-ready cohort
Lisa Vermunt, Graciela Muniz-Terrera, Lea ter Meulen, Colin Veal, Kaj Blennow, Archie Campbell, Isabelle Carrié, Julien Delrieu, Karine Fauria, Gema Huesa Rodríguez, Silvia Ingala, Natalie Jenkins, José Luis Molinuevo, Pierre-Jean Ousset, David Porteous, Niels D Prins, Alina Solomon, Brian D Tom, Henrik Zetterberg, Marissa Zwan, Craig W Ritchie, Philip Scheltens, Gerald Luscan, Anthony J Brookes, Pieter Jelle Visser
Feb 07, 2020
BACKGROUND:Recruitment is often a bottleneck in secondary prevention trials in Alzheimer disease (AD). Furthermore, screen-failure rates in these trials are typically high due to relatively low prevalence of AD pathology in...
Amyloid Recruitment engagement Registries Secondary prevention trials Prescreening Trial-ready cohort
Published by: Alzheimer's research & therapy
The European Prevention of Alzheimer’s Dementia (EPAD) Longitudinal Cohort Study
Craig William Ritchie, G. Muniz-Terrera, M. Kivipelto, A. Solomon, B. Tom, J. L. Molinuevo
Nov 25, 2020
Abstract: Background: The European Prevention of Alzheimer’s Dementia (EPAD) Programme is a pan-European project whose objective is to deliver a platform, adaptive, Phase 2 proof of concept (PoC) trial for the secondary...
Prescreening for European Prevention of Alzheimer Dementia (EPAD) trial-ready cohort
Lisa Vermunt, Graciela Muniz-Terrera, Lea ter Meulen, Colin Veal, Kaj Blennow, Archie Campbell, Isabelle Carrié, Julien Delrieu, Karine Fauria, Gema Huesa Rodríguez, Silvia Ingala, Natalie Jenkins, José Luis Molinuevo, Pierre-Jean Ousset, David Porteous, Niels D Prins, Alina Solomon, Brian D Tom, Henrik Zetterberg, Marissa Zwan, Craig W Ritchie, Philip Scheltens, Gerald Luscan, Anthony J Brookes, Pieter Jelle Visser, IMI-EPAD collaborators
Jan 20, 2020
BACKGROUND: Recruitment is often a bottleneck in secondary prevention trials in Alzheimer disease (AD). Furthermore, screen-failure rates in these trials are typically high due to relatively low prevalence of AD pathology in...
The European Prevention of Alzheimer’s Dementia (EPAD) Longitudinal Cohort Study
Craig William Ritchie, G. Muniz-Terrera, M. Kivipelto, A. Solomon, B. Tom, J. L. Molinuevo
Jun 06, 2020
Abstract: Background: The European Prevention of Alzheimer’s Dementia (EPAD) Programme is a pan-European project whose objective is to deliver a platform, adaptive, Phase 2 proof of concept (PoC) trial for the secondary...
The European Prevention of Alzheimer's Dementia (EPAD) Longitudinal Cohort Study
Prescreening for European Prevention of Alzheimer Dementia (EPAD) trial-ready cohort
Lisa Vermunt, Graciela Muniz-Terrera, Lea ter Meulen, Colin Veal, Kaj Blennow, Archie Campbell, Isabelle Carrié, Julien Delrieu, Karine Fauria, Gema Huesa Rodríguez, Silvia Ingala, Natalie Jenkins, José Luis Molinuevo, Pierre-Jean Ousset, David Porteous, Niels D. Prins, Alina Solomon, Brian D. Tom, Henrik Zetterberg, Marissa Zwan, Craig W. Ritchie, Philip Scheltens, Gerald Luscan, Anthony J. Brookes, Pieter Jelle Visser
Jan 05, 2021
Abstract: Background: Recruitment is often a bottleneck in secondary prevention trials in Alzheimer disease (AD). Furthermore, screen-failure rates in these trials are typically high due to relatively low prevalence of AD...
|
|< |
< |
1 |